Core Points - The State Council has appointed Zheng Zhe as the Deputy Director of the National Health Commission, replacing Cao Xuetao, who has an academic background and previously served as the President of Nankai University [1][3] - Zheng Zhe is known for his expertise in cardiovascular surgery, focusing on clinical, research, and educational work related to heart diseases [1][2] Group 1 - Zheng Zhe's research group primarily focuses on the mechanisms and treatment methods for common cardiovascular diseases, including ischemic heart disease and arrhythmias, with several new devices for atrial fibrillation treatment being developed [2] - The team has established the "China Cardiovascular Surgery Registry Study (CCSR)" to enhance the quality of cardiovascular surgery across collaborating hospitals [2] - Zheng Zhe has led multiple national and provincial research projects, publishing results in prestigious journals and receiving several national science and technology awards [2] Group 2 - Zheng Zhe, born in 1971, is the first "post-70s" leader in the National Health Commission, while the outgoing Cao Xuetao, born in 1964, has a long-standing career in immunology and was elected as an academician of the Chinese Academy of Engineering in 2005 [3] - During Cao Xuetao's tenure as President of Nankai University, he implemented various initiatives to improve the university's academic performance and environment [3]

Group 1: Conference Overview - The conference on high-quality development of public hospitals and academic exchanges in oncology was held at Yantai Yuhuangding Hospital, featuring experts from various leading hospitals and institutions [1] - The event aimed to create a valuable platform for experts in the field of head and neck tumors, promoting standardized diagnosis and treatment in Shandong Province [1] Group 2: Key Presentations - Jiang Xue presented on the importance of transforming clinical research into practical applications, highlighting the "research-production-medical" collaborative development system established at Peking University Third Hospital [2] - Chen Xiaohong discussed advancements in immunotherapy for head and neck tumors, emphasizing the need for multi-center collaborative research to optimize treatment strategies [3] - Li Cheng shared insights on quality management and the MDT (Multidisciplinary Team) model in cancer patient management, showcasing its effectiveness in improving treatment quality and patient outcomes [4] - Song Xicheng explored the neuroscience mechanisms of head and neck tumors, detailing innovative research and the integration of basic and clinical studies [5] Group 3: Academic Discussions - A panel discussion focused on the current challenges in treating advanced head and neck tumors, with experts advocating for a patient-centered approach and the continuous development of MDT management systems [6][7] - The consensus was that the dual context of immunotherapy and big data presents both opportunities and challenges for otolaryngologists [7] Group 4: Future Directions - Song Xicheng emphasized the need for innovative operational thinking and the establishment of new management models based on clinical needs to ensure sustainable development in the field [7] - The conference concluded with a tour of the hospital's advanced research facilities, highlighting the institution's commitment to collaborative innovation and the acceleration of research outcomes [8]